Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is a biotechnology company focused on developing innovative therapies for autoimmune diseases. The company is gaining attention in the market, especially after Wells Fargo maintained its "Overweight" rating with a "hold" action on December 16, 2025. At that time, KYTX was priced at $10.81, and Wells Fargo raised its price target from $31 to $33, as highlighted by TheFly.
The stock has seen a notable increase in options trading activity, with 2,529 call options purchased on a single day, marking a 900% rise from the average daily volume of 253 call options. This surge in activity indicates growing investor interest. On the following day, KYTX opened at $10.82, slightly above the previous day's close, reflecting the market's positive sentiment.
Kyverna Therapeutics has a market capitalization of approximately $474 million, with a price-to-earnings (P/E) ratio of -2.90, indicating that the company is not currently profitable. The stock's beta of 3.65 suggests high volatility compared to the overall market. Despite this, the stock's fifty-day moving average of $7.29 and 200-day moving average of $5.06 show a strong upward trend.
In its latest quarterly earnings report, Kyverna Therapeutics reported an earnings per share (EPS) of -$0.85, beating the consensus estimate of -$0.97 by $0.12. This positive earnings surprise may have contributed to the stock's recent price increase. Analysts expect the company to post an EPS of -3.29 for the current year, indicating ongoing challenges in achieving profitability.
The stock has experienced significant price fluctuations, with a 23.12% increase to $10.81, up by $2.03. During the day, KYTX traded between $10.40 and $13.67, the latter being its highest price in the past year. The stock's lowest price over the past year was $1.78, highlighting its volatile nature. With a trading volume of 18,535,737 shares, KYTX remains a focal point for investors on the NASDAQ exchange.
